Dr. Jie YUAN is a pioneer in AI-driven digital pathology. With a Ph.D. from Tsinghua University and 20+ years in medical imaging, he leads the development of cutting-edge tumor diagnostic platforms that transform pathology workflows with unmatched precision, scalability, and clinical relevance.

Mr. ZENG leads the software development of this advanced AI imaging platform. With decades of experience in software engineering and system integration, he ensures the reliability, scalability, and innovation behind the company’s digital pathology solutions for cancer diagnostics and clinical decision support.

Ms. XU brings extensive expertise in public affairs, data governance, and compliance. With leadership experience at Meituan and ByteDance, she drives IntelliPath’s information strategy, ensuring secure, scalable, and policy-aligned data operations across AI-powered digital pathology systems.

Over 20 years of healthcare and business leadership experience, Ms. Liu oversees operations, strategy, and global expansion, ensuring seamless integration of AI innovation into clinical practice. Her commercial acumen and executional strength drive IntelliPath’s mission to revolutionize digital pathology worldwide.

Mr. Jun Shi leads IntelliPath’s overseas sales strategy, focusing on developing countries where affordable digital pathology can have the greatest impact. With extensive international management experience across 20+ countries, he drives market entry, builds strategic partnerships with hospitals and government agencies, and negotiates distribution agreements. Stationed abroad, Mr. Shi oversees customer engagement, sales execution, and brand positioning to expand IntelliPath’s footprint. His insights into emerging markets provide critical guidance for adapting products to local needs, ensuring IntelliPath delivers accessible, cost-effective diagnostic solutions while achieving sustainable growth in under-resourced healthcare systems.